<DOC>
	<DOCNO>NCT02545842</DOCNO>
	<brief_summary>Primary Objective : To identify best fast plasma glucose ( FPG ) target Chinese type 2 diabetes patient use insulin glargine provide high control rate glycated hemoglobin ( HbA1c ) &lt; 7 % . Secondary Objectives : The control rate HbA1c ≤6.5 % achievement . The control rate HbA1c &lt; 7.0 % patient achieve FPG target . The percentage HbA1c &lt; 7 % without hypoglycemia . The percentage patient achieve FPG target without hypoglycemia . The percentage patient achieve FPG target post prandial glucose ( PPG ) target ( 2-hour post breakfast &lt; 10 mmol/L ) .</brief_summary>
	<brief_title>Assessment Study Three Different Fasting Plasma Glucose Targets Chinese Patients With Type 2 Diabetes Mellitus ( BEYOND III/FPG GOAL )</brief_title>
	<detailed_description>The study duration patient 27 week .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Inclusion criterion : 18 65 year old . Type 2 diabetes patient insufficient control 13 oral antihyperglycemic drug ( OADs ) stable dose least 3 month : If 1 OAD , provide follow dos ( include limit ) : αglucosidase inhibitor : 100mg , three time day ( tid ) ; metformin : 1.52.0 g/day ; sulphonylureas : submaximum ( half dose ) maximum tolerate dose ; thiazolidinediones : eg . pioglitazone , 3040 mg/day . Besides medication list , 1 OAD , others maximum tolerate dose allow package insert . If 23 OADs , range dose acceptable . HbA1c &gt; 7 % , ≤10.5 % . FPG &gt; 7 mmol/L . Body mass index ( BMI ) ≥20 kg/m^2 , ≤40 kg/m^2 . Diabetes duration ≥1 year . Physician decide patient willing start basal insulin ( BI ) treatment . Willing join study sign inform consent . Exclusion criterion : Type 1 diabetes patient . Patients acute diabetic complication ( include unexplained severe hypoglycemia last 6 month ) . Previous treatment insulin 1 month cumulatively last 1 year , treatment insulin last 3 month screen . Known hypoglycemia unawareness recurrent hypoglycemia . Hypersensitivity study drug excipients . Any clinically significant acute major organ systemic disease , situation judge Investigator , difficult 24 week followup . Pregnancy breastfeed woman . Have mental disorder , lack selfcontrol able express accurately . Involved another clinical trial simultaneously within 1 month start trial . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>